Caspase 1 inhibitors, such as VX-765, and soluble analogs of Parthenolide (an anti-inflammatory sesquiterpene lactone compound) can play a therapeutic role in MDS. This evidence concerns the gene CASP1 and myelodysplastic syndrome.